The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Gottfried E. Konecny

Division of Hematology-Oncology

Department of Medicine

University of California at Los Angeles

School of Medicine

USA

[email]@ucla.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology-Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine, USA. 2001 - 2006
  • University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095-1678, USA. 2004
  • Department of Medicine, UCLA School of Medicine, 90095-1678, USA. 2001

References

  1. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Konecny, G.E., Pegram, M.D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D.W., Spehar, G., Mullin, R.J., Keith, B.R., Gilmer, T.M., Berger, M., Podratz, K.C., Slamon, D.J. Cancer Res. (2006) [Pubmed]
  2. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Konecny, G.E., Pegram, M.D. Oncology (Williston Park, N.Y.) (2004) [Pubmed]
  3. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., Hepp, H., Slamon, D., Pegram, M. Clin. Cancer Res. (2001) [Pubmed]
  4. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Konecny, G., Untch, M., Arboleda, J., Wilson, C., Kahlert, S., Boettcher, B., Felber, M., Beryt, M., Lude, S., Hepp, H., Slamon, D., Pegram, M. Clin. Cancer Res. (2001) [Pubmed]
  5. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Konecny, G., Untch, M., Slamon, D., Beryt, M., Kahlert, S., Felber, M., Langer, E., Lude, S., Hepp, H., Pegram, M. Breast Cancer Res. Treat. (2001) [Pubmed]
  6. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Konecny, G., Fritz, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H., Slamon, D., Pegram, M. Breast Cancer Res. Treat. (2001) [Pubmed]
 
WikiGenes - Universities